SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs post-earnings selloff is being tied to softer fourth-quarter guidance, a lower advertising outlook, and slowing growth, despite an earnings beat. Traders are split between viewing the drop as an overreaction and buying opportunity or seeing further downside amid content and competition concerns.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is drawing attention after a strong quarterly earnings report and a wave of analyst upgrades, with traders focusing on rapid growth in its AI-compute business alongside its space and Starlink operations. Bullish reactions point to growth potential and possible Tesla ties, while skeptics cite heavy capital spending, a large share unlock and uncertainty around any merger.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro sharply raised its preliminary fiscal Q1 outlook on stronger AI-platform demand and improved gross-margin expectations, driving a rally. Traders largely welcomed the demand signal and speculated about a short squeeze, while skeptics questioned whether margins, cash flow and execution can sustain the move.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&Ts earnings beat and higher outlook failed to prevent a selloff, with traders pointing to postpaid phone additions falling short of expectations. The reaction is debated as either concern about subscriber momentum and lingering SpaceX competition or an overreaction to otherwise solid results, with some investors buying the dip.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is caught in a sharp memory-chip selloff and rebound debate, with traders pointing to concerns about Chinese competitor CXMT, South Korean market weakness and broader doubts about AI spending. Bulls argue those fears overstate the threat to NAND demand and cite tight memory supply and upcoming earnings, while bears warn that memorys cyclical risks and the wider tech unwind could keep pressure on shares.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings have traders focused on Google Cloud growth and whether AI investments can generate returns, amid widespread concern about heavy capital spending and speculation it could rise further. The debate is split between dip-buyers citing Alphabets AI and cloud businesses and bearish traders worried about spending, search disruption, and the shares persistent weakness.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is drawing attention for its sharp pullback and weak price action ahead of earnings, with traders watching whether cloud growth and AI investment can translate into returns. The discussion is split between dip-buyers citing its AI and quantum-computing progress and bearish traders focused on underperformance, technical support, and heavy capital spending.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives upsized SATS preferred offering and continued Bitcoin purchases are driving attention as the company expands its crypto treasury. Traders are divided between viewing the accumulation as bullish Bitcoin exposure and warning that preferred dividend costs and dilution could weigh on common shareholders.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is under pressure alongside neocloud peers as traders focus on AI infrastructure financing risks, CoreWeave-related concerns, and a cautious analyst outlook. Bulls counter that compute demand remains strong and Nebius is less exposed to debt pressures, while the community debates whether those fundamentals can outweigh sector-wide selling.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

FDA approval of ORLADEYO oral pellets is driving discussion, with bulls highlighting easier administration and potential to reach patients who struggle with capsules, while skeptics question the near-term impact on the share price. Frustration over BCRXs weak trading and the wait for Netherton and navenibart data remains prominent.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure ImprovementsPR NewswireLAUSANNE, Switzerland, Oct. 8, 2026$86.6 Million...

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference PR Newswire LAUSANNE, Switzerland, Sept. 3, 2026 LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT...

ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

ADC Therapeutics Q2 2026 Earnings Call Transcript

On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financialread more...

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates PR Newswire LAUSANNE, Switzerland, Aug. 13, 2026 Second quarter 2026 net product revenue of $18.6 million...

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 PR Newswire LAUSANNE, Switzerland, Aug. 6, 2026 LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC...

Alkermes (ALKS) Reports Break-Even Earnings for Q2

Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement Grant PR Newswire LAUSANNE, Switzerland, July 1, 2026 LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ --ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Adc Therapeutics SA

ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>ADC Therapeutics said that the reduction in workforce is driven by the expected completion of LOTIS-5 and LOTIS-7 trials.</li><li>The company expects to deliver on its key clinical, regulatory, and manufacturing activities while managing commercial activities to aid ZYNLONTA.</li><li>The company is now preparing for a scheduled pre-supplemental Biologics License Application (pre-sBLA) with the FDA in August 2026.&nbsp;</li></ul>ADC Therapeutics (ADCT) on Wednesday announced it would cut its global workforce by about 17% to focus on its ZYNLONTA franchise and regulatory and clinical milestones.At the time of writing, ADCT stock was down 2.6% during Wednesday’s premarket session.ADC Therapeutics said the reduction in workforce is driven by the expected completion of the LOTIS-5 and LOTIS-7 trials, both evaluating its targeted cancer therapy ZYNLONTA this year, and operational efficiencies.&nbsp;<h2 class="st-heading-2">ADCT Aims To Increase Financial Flexibility</h2>With these changes, the company expects to deliver on its&nbsp;key clinical, regulatory, and manufacturing activities, while managing commercial activities to aid ZYNLONTA,&nbsp;ADC Therapeutics noted."This strategic reorganization will enable us to increase our financial flexibility as we prepare for upcoming LOTIS-5 regulatory milestones and continue building on the broader opportunity for ZYNLONTA through LOTIS-7 and support for the indolent lymphoma investigator-initiated trials (IITs),” said Ameet Mallik, Chief Executive Officer at ADC Therapeutics.The firm expects to generate annualized cost savings of about $10 million and incur one-time pre-tax charges of about $3 million. The majority of these costs will be recognized in the second quarter of 2026, according to the company.&nbsp;ADC Therapeutics expects its cash runway to extend at least through 2028.<h2 class="st-heading-2">ADCT’s Regulatory Pipeline</h2>The company is now preparing for a scheduled pre-supplemental Biologics License Application (pre-sBLA) with the Food and Drug Administration (FDA) in August 2026.&nbsp;ADC Therapeutics aims to discuss a possible regulatory way forward for ZYNLONTA in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), a type of blood cancer that has returned or hasn’t responded to previous therapy, following the topline data from the Phase 3 LOTIS-5 trial.<h2 class="st-heading-2">What Retail Thinks Of ADCT</h2>On Stocktwits, retail sentiment surrounding the stock has remained ‘bearish’ amid ‘low’ message volumes in the past 24 hours.One user on Stocktwits said that the reorganization shows the company’s commitment to disciplined spending. <stembedurl>https://stocktwits.com/Spartrap/message/657285140</stembedurl>ADCT stock has declined by more than 67% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-fcel-stock-surging-today-june-24-2026/cZKyBvGR7fX">Why Is FCEL Stock Surging Today?</a>

In this photo illustration, the ADC Therapeutics logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ADC Therapeutics expects to generate annualized cost savings of about $10 million and incur one-time pre-tax charges of about $3 million.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.53
Prev Close	$1.52
Open	$1.51
Dividend Yield	0.00%
50-Day Moving Average	$1.23
Beta	1.67
Avg. Volume	1.49M
PE Ratio	-2.29

52-Week High	$4.98
52-Week Low	$0.7796
Market Capitalization	$194.05M
EPS (Annual)	-$1.12
Price to Book	-0.85
Revenue Per Employee	$421,538.86

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADCT Fundamentals